Evidence map›Paper›PMID 41800258›Full record

ArticleInternational journal of biological sciences2026

Triptonide-mediated PTGS2 Inhibition Induces Autophagic Cell Death to Suppress the Progression of Triple-negative Breast Cancer and Epithelial Ovarian Cancer.

Kunxiang Gong, Kai Song, Haotian Wang, Linye Li, Xiaomin Sun, Lingling Sun, Wenbo Hao, Zhe-Sheng Chen, Yinger Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kunxiang GongScientific Research Center, First School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China.
Kai SongGuangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Haotian WangInstitute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
Linye LiInstitute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
Xiaomin SunDepartment of Traditional Chinese Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
Lingling SunDepartment of Oncology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China.
Wenbo HaoInstitute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
Zhe-Sheng ChenDepartments of Pharmaceutical Science, College of Pharmacy and Health Science, St John's University, Queens, NY 11439, USA.
Yinger HuangScientific Research Center, First School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) and epithelial ovarian cancer (EOC) pose notable threats to the health of women. Given the poor prognosis associated with TNBC and EOC, new therapeutic agents must be explored urgently. Here, we identified triptonide (TN), a natural compound derived from the traditional Chinese herb

Indexed as

Autophagic Cell DeathCarcinoma, Ovarian EpithelialCyclooxygenase 2Ovarian NeoplasmsTriple Negative Breast NeoplasmsTriterpenesAnimalsAutophagyCell Line, TumorCell ProliferationFemaleHumansMiceSignal TransductionCyclooxygenase 2PTGS2 protein, humantriptonideTriterpenesAutophagic cell deathEpithelial ovarian cancerJAK/STAT3 signalingProstaglandin G/H Synthase 2Triple-negative breast cancerTriptonide

Identifiers

PMID41800258
PMCPMC12965061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.